Cell Robotics Completes Private Placement
ALBUQUERQUE, N.M., Feb. 28 -- Cell Robotics International has announced the completion of a non-brokered, $1.08-million private placement involving 450,000 shares of the company's common stock. The transaction also included an option to purchase an additional 50,000 shares of common stock under the same terms during the next eight weeks. In addition, the investor is to be appointed to the current board of directors and to be nominated to the board of directors for vote by the shareholders at the company's annual meeting in May 2000. Cell Robotics described the investor as an experienced international technologist and manager who is the president of his own engineering company.
The company plans to use the proceeds from this private placement primarily for the manufacturing, sales and marketing efforts of its proprietary laser device, the Personal Lasette. Cell Robotics said the Personal Lasette is the only FDA-cleared alternative to the needle or steel blade lancet currently available for diabetics to use in drawing blood to test their glucose levels.
LATEST NEWS
- Quantinuum Launches 56-Qubit Quantum Computer: Week in Brief: 6/7/2024
Jun 7, 2024
- Atom Computing Lands Investment, Expands Overseas
Jun 7, 2024
- Optogenetic Stimulation Enables Fatigue-Resistant Muscle Control
Jun 6, 2024
- Quandela Launches Pilot Line for Qubit Devices
Jun 6, 2024
- Lattice Semiconductor Adds Interim CEO
Jun 6, 2024
- On-Chip Microcomb Laser Provides Greater Control
Jun 5, 2024
- Flexible, Stretchable Device Addresses Tuning Limitations in Structural Color
Jun 5, 2024
- Fusion Startup Xcimer Raises $100M, Plans Laser Prototype
Jun 4, 2024